Document:

Exhibit
10.1

 

PROMISSORY
NOTE

 

	$200,000	June
    22, 2020 (the “Issuance Date”)

 

FOR
VALUE RECEIVED, NanoVibronix, Inc. (“Borrower”) promises to pay Globis Capital Partners, L.P. (“Noteholder”)
in lawful money of the United States of America, the amount of $200,000 plus accrued and unpaid interest (the “Note”)
on the earlier of (a) June 22, 2021, and (b) the date on which all amounts under this Note shall become due and payable pursuant
to Section 5 (the “Payment Date”)

 

1.
Interest. Interest shall accrue on the outstanding principal balance of this Note at the per annum rate of 10% commencing
on the Issuance Date. All interest shall be due and payable in arrears on the Payment Date or the earlier payment in full of this
Note.

 

2.
Manner of Payment. The amount of this Note shall be paid by Borrower to Noteholder by wire transfer of immediately available
funds to an account or accounts designated by Noteholder in writing on the Payment Date.

 

3.
Prepayment. Borrower may, without premium or penalty, at any time and from time to time, prepay all or any portion of this
Note.

 

4.
Events of Default. The occurrence and continuance of any of the following shall constitute an “Event of Default”
hereunder:

 

(a)
Failure to Pay. The Borrower fails to pay the full amount of the Note on the Payment Date.

 

(b)
Bankruptcy.

 

(i)
the Borrower commences any case, proceeding or other action (A) under any existing or future law relating to bankruptcy, insolvency,
reorganization, or other relief of debtors, seeking to have an order for relief entered with respect to it, or seeking to adjudicate
it as bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, winding-up, liquidation, dissolution, composition
or other relief with respect to it or its debts or (B) seeking appointment of a receiver, trustee, custodian, conservator or other
similar official for it or for all or any substantial part of its assets, or the Borrower makes a general assignment for the benefit
of its creditors;

 

(ii)
there is commenced against the Borrower any case, proceeding or other action of a nature referred to in Section 4(b)(i) above
which (A) results in the entry of an order for relief or any such adjudication or appointment or (ii) remains undismissed, undischarged
or unbonded for a period of 30 days;

 

(iii)
there is commenced against the Borrower any case, proceeding or other action seeking issuance of a warrant of attachment, execution
or similar process against all or any substantial part of its assets which results in the entry of an order for any such relief
which has not been vacated, discharged, or stayed or bonded pending appeal within 30 days from the entry thereof; or

 

(iv)
the Borrower takes any action in furtherance of, or indicating its consent to, approval of, or acquiescence in, any of the acts
set forth in Section 4(b)(i), Section 4(b)(ii) or Section 4(b)(iii) above.

 

    	 

    	 	 	 

    

 

5.
Remedies. Upon the occurrence of any Event of Default and at any time thereafter during the continuance of such Event of
Default, the Noteholder may at its option, by written notice to the Borrower (a) declare the entire principal amount of this Note,
together with all accrued interest thereon and all other amounts payable hereunder, immediately due and payable; and/or (b) exercise
any or all of its rights, powers or remedies under applicable law; provided, however that, if an Event of Default described in
Section 4(b) shall occur, the principal of and accrued interest on this loan shall become immediately due and payable without
any notice, declaration or other act on the part of the Noteholder.

 

6.
Contracted for Interest. The Noteholder agrees to pay an effective contracted amount as provided in this Note. The Noteholder
understands and believes that this transaction complies with the usury laws of the state of New York; however, if any other charges
in connection with this transaction are ever determined to exceed the maximum amount permitted by law, then the Noteholder agrees
that (a) the amount of interest or charges payable pursuant to this transaction shall be reduced to the maximum amount permitted
by law; and (b) any excess amount previously collected from the Noteholder in connection with this transaction, which exceeded
the maximum amount permitted by law, will be credited against the principal balance then outstanding hereunder. If the outstanding
principal balance hereunder has been paid in full, the excess amount paid will be refunded to the Noteholder.

 

7.
Enforcement Expenses. The Borrower agrees to pay all costs and expenses of enforcement of this Note, including, without
limitation, reasonable attorneys’ fees and expenses.

 

8.
Severability. If any provision in this Note is held invalid or unenforceable by any court of competent jurisdiction, the
other provisions of this Note will remain in full force and effect. Any provision of this Note held invalid or unenforceable only
in part or degree will remain in full force and effect to the extent not held invalid or unenforceable.

 

9.
Governing Law. This Note will be governed by the laws of the State of New York without regard to conflicts of laws principles.

 

10.
Parties in Interest. This Note shall bind the Borrower and its successors and assigns. This Note shall not be assigned,
pledged or transferred by Noteholder without the express prior written consent of the Borrower, except by will or, in default
thereof, by operation of law.

 

11.
Section Headings; Construction. The headings of Sections in this Note are provided for convenience only and will not affect
its construction or interpretation. All references to “Section” or “Sections” refer to the corresponding
Section or Sections of this Note unless otherwise specified. All words used in this Note will be construed to be of such gender
or number as the circumstances require. Unless otherwise expressly provided, the words “hereof” and “hereunder”
and similar references refer to this Note in its entirety and not to any specific section or subsection hereof.

 

IN
WITNESS WHEREOF, Borrower has executed and delivered this Note as of the date first written above.

 

	 	NanoVibronix,
    Inc. 
	 	 	 
	 	 	 
	 	By:	Brian
    Murphy
	 	Title:	Chief
    Executive OfficerExhibit
10.2

 

NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT
BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM
REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD
PURSUANT TO RULE 144 OR RULE 144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH
A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

NanoVibronix,
Inc.

 

Warrant
To Purchase Capital Stock

 

Warrant
No.: 2020-A

Date
of Issuance: June 22, 2020 (“Issuance Date”)

 

NanoVibronix,
Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, Globis Capital Partners, L.P., the registered holder hereof or its
permitted assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from
the Company, at the Exercise Price (as defined below) then in effect, upon exercise of this Warrant to Purchase Capital Stock
(including any Warrants to Purchase Capital Stock issued in exchange, transfer or replacement hereof, this “Warrant”),
at any time or times after the six month anniversary of the Date of Issuance, but not after 11:59 p.m., New York time, on June
22, 2027 at the election of the Holder, One Hundred Thousand (100,000) (subject to adjustment as provided herein) fully paid and
nonassessable shares of Common Stock (as defined below) (collectively, the “Warrant Shares”).

 

1. EXERCISE OF WARRANT.

 

(a)
Mechanics of Exercise. Subject to the terms and
conditions hereof, this Warrant may be exercised by the Holder on any day after the Issuance Date, in whole or in part, by delivery
(whether via facsimile or otherwise) of a written notice, in the form attached hereto as Exhibit A (the “Exercise
Notice”), of the Holder’s election to exercise this Warrant. Within one (1) Business Day following an exercise
of this Warrant as aforesaid, the Holder shall deliver payment to the Company of an amount in cash by wire transfer of immediately
available funds equal to the Exercise Price in effect on the date of such exercise multiplied by the number of Warrant Shares
as to which this Warrant was so exercised or, if available, in the manner set forth in Section 1(c) below (the “Aggregate
Exercise Price”). The Holder shall not be required to deliver the original of this Warrant in order to effect an
exercise hereunder. Execution and delivery of an Exercise Notice with respect to less than all of the Warrant Shares shall have
the same effect as cancellation of the original of this Warrant and issuance of a new Warrant evidencing the right to purchase
the remaining number of Warrant Shares. Execution and delivery of an Exercise Notice for all of the then-remaining Warrant Shares
shall have the same effect as cancellation of the original of this Warrant after delivery of the Warrant Shares in accordance
with the terms hereof. On or before the first (1st) Business Day following the date on which the Company has received
an Exercise Notice and payment of the Aggregate Exercise Price for the number of Warrant Shares for which this Warrant was so
exercised, the Company shall transmit by facsimile an acknowledgment of confirmation of receipt of such Exercise Notice to the
Holder and the Company’s transfer agent for the Warrant Shares, if any. On or before the third (3rd) Business
Day following the date on which the Company has received such Exercise Notice and payment of the Aggregate Exercise Price for
the number of Warrant Shares for which this Warrant was so exercised, the Company shall issue and deliver to the Holder or, at
the Holder’s instruction pursuant to the Exercise Notice, the Holder’s agent or designee, in each case, sent by reputable
overnight courier to the address as specified in the applicable Exercise Notice, a certificate, registered in the Company’s
share register in the name of the Holder or its designee (as indicated in the applicable Exercise Notice), for the number of shares
of Series E Convertible Stock to which the Holder is entitled pursuant to such exercise. Upon delivery of an Exercise Notice and
payment of the Aggregate Exercise Price for the number of Warrant Shares for which this Warrant was so exercised, the Holder shall
be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant
has been exercised, irrespective of the date of delivery of the certificates evidencing such Warrant Shares.

 

    	 

    	 	 	 

    

 

(b)
Exercise Price. For purposes of this Warrant, “Exercise Price” means a price per Warrant
Share equal to $2.50, subject to adjustment as provided herein.

 

(c)
Cashless Exercise.

 

This
Warrant may also be exercised, in whole or in part, by means of a “cashless exercise,” in which event the Company
shall issue to the Holder the number of Warrant Shares determined as follows:

 

	 	 

        X=
	
	 	 	 
	Where	X=	the
    number of Warrant Shares to be issued to the Holder.
	 	 	 
	 	Y=	the
    number of Warrant Shares purchasable upon exercise of all of the Warrant or, if only a portion of the Warrant is being exercised,
    the portion of the Warrant being exercised.
	 	 	 
	 	A=	the
    Exercise Price.
	 	 	 
	 	B=	the
    Per Share Market Value of one Warrant Share on the Business Day immediately preceding the date of such election.

 

(d) Fractional
Shares. The Company shall not be required to issue or cause to be issued fractional Warrant Shares on the exercise
of this Warrant. If any fraction of a Warrant Share would, except for the provisions of this Section, be issuable upon
exercise of this Warrant, the number of Warrant Shares to be issued will be rounded up to the nearest whole share.

 

(e) Insufficient
Authorized Shares. From and after the Issuance Date, the Company shall at all times keep reserved for issuance
under this Warrant a number of shares of Common Stock as shall be necessary to satisfy the Company’s obligation to
issue shares of Common Stock hereunder. If, notwithstanding the foregoing, and not in limitation thereof, at any time while
this Warrant remains outstanding the Company does not have a sufficient number of authorized and unreserved shares of Common
Stock (an “Authorized Share Failure”) to satisfy its obligation to reserve for issuance upon
exercise of this Warrant (the “Required Reserve Amount”), then the Company shall promptly take all
action necessary to increase the Company’s authorized shares of Common Stock, as applicable, to an amount sufficient to
allow the Company to reserve the Required Reserve Amount. Without limiting the generality of the foregoing sentence, if the
approval of the stockholders of the Company is required, as soon as practicable after the date of the occurrence of an
Authorized Share Failure, but in no event later than ninety (90) days after the occurrence of such Authorized Share Failure,
the Company shall hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of
Common Stock. In connection with such meeting, the Company shall provide each stockholder with a proxy statement and shall
use its reasonable best efforts to solicit its stockholders’ approval of such increase in authorized shares Common
Stock, and to cause its board of directors to recommend to the stockholders that they approve such proposal.

 

    	 	2	 

    	 	 	 

    

 

(f) Holder’s
Exercise Limitations. The Company shall not affect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 1 or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Exercise Notice, the Holder (together with the Holder’s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would
beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares
of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall
exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion
of this Warrant beneficially owned by the Holder or any of its affiliates and (ii) exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock
Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially
owned by the Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this Section
1(f), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and
regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder
that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 1(f)
applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder
together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the
Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this
Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which
portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall
have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group
status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and
regulations promulgated thereunder. For purposes of this Section 1(f), in determining the number of outstanding shares of
Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s
most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by
the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of
Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two Business Days confirm
orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of
outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the
Company, including this Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares
of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 9.99% of the number of
shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable
upon exercise of this Warrant. The Holder, upon not less than 61 days’ prior written notice to the Company, may
increase or decrease the Beneficial Ownership Limitation provisions of this Section 1(f), provided that the Beneficial
Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after
giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions
of this Section 1(f) shall continue to apply. Any such increase or decrease will not be effective until the 61st day after
such written notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a
manner otherwise than in strict conformity with the terms of this Section 1(f) to correct this paragraph (or any portion
hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make
changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this
paragraph shall apply to a successor holder of this Warrant. The Beneficial Ownership Limitation provisions of this Section
1(f) may be waived at the election of the Holder upon not less than 61 days’ prior written notice to the Company. Any
such waiver will not be effective and the provisions of this paragraph shall continue to apply until the 61st day (or later,
if stated in the notice) after such notice of waiver is delivered to the Company.

 

    	 	3	 

    	 	 	 

    

 

2. ADJUSTMENT
OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES. Without limiting any provision of Section 4, if the Company, at any time
after the Issuance Date, (i) pays a stock dividend on one or more classes of its then outstanding shares of Common Stock, or
otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock, (ii) subdivides (by
any stock split, stock dividend, recapitalization or otherwise) one or more classes of its then outstanding shares of Common
Stock into a larger number of shares or (iii) combines (by combination, reverse stock split or otherwise) one or more classes
of its then outstanding shares of Common Stock into a smaller number of shares, then in each such case (A) the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock outstanding
immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event and (B) the number of shares of Common Stock for which this Warrant is exercisable immediately
after the occurrence of any such event shall be adjusted to equal the number of shares of Common Stock which a record holder
of the same number of shares of Common Stock for which this Warrant is exercisable immediately prior to the occurrence of
such event would own or be entitled to receive after the happening of such event. Any adjustment made pursuant to clause (i)
of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to
receive such dividend or distribution, and any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become
effective immediately after the effective date of such subdivision or combination. If any event requiring an adjustment under
this paragraph occurs during the period that an Exercise Price is used in any calculation hereunder, then in such calculation
such Exercise Price shall be adjusted appropriately to reflect such event.

 

 3. REPRESENTATIONS AND WARRANTES OF HOLDER. The Holder hereby represents and warrants to the Company that:

 

(a)
Holder acknowledges that this Warrant is issued to the Holder in reliance upon the Holder’s
representation to the Company that this Warrant will be acquired for investment for the Holder’s own account, not as a nominee
or agent, and not with a view to the resale or distribution of any part thereof, and that such Holder has no present intention
of selling, granting any participation in, or otherwise distributing the same. Holder further represents that the Holder does
not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such
person or to any third person, with respect to this Warrant.

 

(b)
Holder is an investor in securities of companies in the development stage and acknowledges that it, he or she is able to fend
for itself, himself or herself, can bear the economic risk of its, his or her investment, and has such knowledge and
experience in financial or business matters that it, he or she is capable of evaluating the merits and risks of the
investment in this Warrant. Holder also represents it, he or she has not been organized solely for the purpose of acquiring
this Warrant.

 

(c)
Holder is an “accredited investor” within the meaning of Rule 501 of Regulation D, as presently in effect, as
promulgated by the Securities and Exchange Commission (the “SEC”) under the Securities
Act.

 

    	 	4	 

    	 	 	 

    

 

(d) Holder
understands that this Warrant is characterized as a “restricted security” under the federal securities laws inasmuch
as it is being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable
regulations such securities may be resold without registration under the Securities Act only in certain limited circumstances.
In this connection, Holder represents that it is familiar with Rule 144 as promulgated by the SEC under the Securities Act, as
presently in effect, and understands the resale limitations imposed thereby and by the Securities Act.

 

 4. FUNDAMENTAL TRANSACTIONS.

 

(a) Fundamental
Transactions. Prior to the consummation of each Fundamental Transaction pursuant to which holders of shares of Common
Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a
“Corporate Event”), the Company shall make appropriate provision to insure that the Holder will
thereafter have the right to receive upon an exercise of this Warrant at any time after the consummation of the applicable
Fundamental Transaction but prior to the Expiration Date, in lieu of the shares of the Common Stock (or other securities,
cash, assets or other property) issuable upon the exercise of the Warrant prior to such Fundamental Transaction, such shares
of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription
rights) which the Holder would have been entitled to receive upon the happening of the applicable Fundamental Transaction had
this Warrant been exercised immediately prior to the applicable Fundamental Transaction (without regard to any limitations on
the exercise of this Warrant). Provision made pursuant to the preceding sentence shall be in a form and substance reasonably
satisfactory to the Holder.

 

(b) Application.
The provisions of this Section 4 shall apply similarly and equally to successive Fundamental Transactions and Corporate Events.

 

5. NONCIRCUMVENTION.
The Company hereby covenants and agrees that the Company will not, by amendment of the Company’s certificate of incorporation,
the Company’s bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution,
issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as
may be required to protect the rights of the Holder. Without limiting the generality of the foregoing, the Company (i) shall not
increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then
in effect and (ii) shall take all such actions as may be reasonably necessary or appropriate in order that the Company may validly
and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant.

 

6. WARRANT
HOLDER NOT DEEMED A STOCKHOLDER. Except as otherwise specifically provided herein, the Holder, solely in its capacity as a
holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company
for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in its capacity as
the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to
any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance
or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the
Holder of the Warrant Shares which it is then entitled to receive upon the due exercise of this Warrant. In addition, nothing
contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise
of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors
of the Company. Notwithstanding this Section 6, the Company shall provide the Holder with copies of the same notices and other
information given to the stockholders of the Company generally, contemporaneously with the giving thereof to the stockholders.

 

    	 	5	 

    	 	 	 

    

 

7. REISSUANCE
OF WARRANTS.

 

(a) Transfer
of Warrant. If this Warrant is to be transferred, the Holder shall surrender this Warrant to the Company, whereupon the
Company will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with Section 7(d)),
registered as the Holder may request, representing the right to purchase the number of Warrant Shares being transferred by
the Holder and, if less than the total number of Warrant Shares then underlying this Warrant is being transferred, a new
Warrant (in accordance with Section 7(d)) to the Holder representing the right to purchase the number of Warrant Shares not
being transferred.

 

(b)
Lost, Stolen or Mutilated Warrant. Upon
receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this
Warrant (as to which a written certification and the indemnification contemplated below shall suffice as such evidence), and,
in the case of loss, theft or destruction, of any indemnification undertaking by the Holder satisfactory to the Company and, in
the case of mutilation, upon surrender and cancellation of this Warrant, the Company shall execute and deliver to the Holder a
new Warrant (in accordance with Section 7(d)) representing the right to purchase the Warrant Shares then underlying this Warrant.

 

(c)
Exchangeable for Multiple Warrants. This
Warrant is exchangeable, upon the surrender hereof by the Holder at the principal office of the Company, for a new Warrant or
Warrants (in accordance with Section 7(d)) representing in the aggregate the right to purchase the number of Warrant Shares then
underlying this Warrant, and each such new Warrant will represent the right to purchase such portion of such Warrant Shares as
is designated by the Holder at the time of such surrender; provided, however, no warrants for fractional shares of Common Stock
shall be given.

 

(d)
Issuance of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant,
such new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant,
the right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to
Sections 7(a) or 7(c), the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying
the other new Warrants issued in connection with such issuance, does not exceed the number of Warrant Shares then underlying this
Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date,
and (iv) shall have the same rights and conditions as this Warrant.

 

8. NOTICES.
Except as may be otherwise provided herein, all notices, requests, waivers and other communications made pursuant to this Warrant
shall be in writing to the addresses set forth on the signature pages hereof and shall be deemed effectively given: (i) upon personal
delivery to the party to be notified, (ii) when sent by confirmed electronic mail or facsimile if sent during normal business
hours of the recipient; if not, then on the next business day, (iii) five days after having been sent by registered or certified
mail, return receipt requested, postage prepaid, or (iv) one (1) day after deposit with an internationally recognized overnight
courier, specifying next day delivery, with written verification of receipt.

 

9. NOTICES
OF CERTAIN CORPORATE ACTIONS. The Company shall provide the Holder with prompt written notice of all actions taken pursuant
to this Warrant, including in reasonable detail a description of such action and the reason therefor. Without limiting the generality
of the foregoing, the Company will give written notice to the Holder (i) immediately upon each adjustment of the Exercise Price
and the number of Warrant Shares, setting forth in reasonable detail, and certifying, the calculation of such adjustment(s) and
(ii) at least fifteen (15) days prior to the date on which the Company closes its books or takes a record (A) with respect to
any dividend or distribution upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of any Options,
Convertible Securities or rights to purchase stock, warrants, securities or other property to holders of shares of Common Stock
or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each
case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the
Holder and (iii) at least ten (10) Business Days prior to the consummation of any Fundamental Transaction.

 

    	 	6	 

    	 	 	 

    

 

10. AMENDMENT
AND WAIVER. Except as otherwise provided herein, the provisions of this Warrant may be amended and the Company may take any
action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the
written consent of the Holder. No waiver shall be effective unless it is in writing and signed by an authorized representative
of the waiving party.

 

11. SEVERABILITY.
If any provision of this Warrant is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent
jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the
broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect
the validity of the remaining provisions of this Warrant so long as this Warrant as so modified continues to express, without
material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity
or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations
of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will
endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s),
the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

12. GOVERNING
LAW. This Warrant shall be governed by and construed and enforced in accordance with, and all questions concerning the construction,
validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of New York, without
giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions)
that would cause the application of the laws of any jurisdictions other than the State of New York.

 

13. REMEDIES,
CHARACTERIZATION, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies provided in this Warrant shall be cumulative
and in addition to all other remedies available under this Warrant at law or in equity (including a decree of specific performance
and/or other injunctive relief), and nothing herein shall limit the right of the Holder to pursue actual damages for any failure
by the Company to comply with the terms of this Warrant. The Company covenants to the Holder that there shall be no characterization
concerning this instrument other than as expressly provided herein. Amounts set forth or provided for herein with respect to payments,
exercises and the like (and the computation thereof) shall be the amounts to be received by the Holder and shall not, except as
expressly provided herein, be subject to any other obligation of the Company (or the performance thereof). The Company acknowledges
that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any
such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the holder
of this Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without
the necessity of showing economic loss and without any bond or other security being required. The Company shall provide all information
and documentation to the Holder that is requested by the Holder to enable the Holder to confirm the Company’s compliance
with the terms and conditions of this Warrant (including, without limitation, compliance with Section 2 hereof). The issuance
of shares and certificates for shares as contemplated hereby upon the exercise of this Warrant shall be made without charge to
the Holder or such shares for any issuance tax or other costs in respect thereof, provided that the Company shall not be required
to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of any certificate in a name
other than the Holder or its agent on its behalf.

 

14. TRANSFER.
This Warrant may not be offered for sale, sold, transferred or assigned by the Holder except in a manner consistent with the restrictive
legend on the first page of this Warrant; provided, however, that no such assignment shall relieve the Holder of
its obligations hereunder if such assignee fails to perform such obligations.

 

    	 	7	 

    	 	 	 

    

 

15. CERTAIN
DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:

 

(a) “Affiliate”
means any person or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or is
under common control with a person or entity, as such terms are used in and construed under Rule 144 under the Securities Act.
With respect to a Holder, any investment fund or managed account that is managed on a discretionary basis by the same investment
manager as such Holder will be deemed to be an Affiliate of such Holder.

 

(b) “Business
Day” means any day other than Saturday, Sunday or other day on which commercial banks in the city of New York, New
York are authorized or required by law to remain closed.

 

(c) “Common
Stock” means the common stock of the Company.

 

(d) “Common
Stock Equivalent” means any Convertible Security or warrant, Option or other right to subscribe for or purchase
any share of Common Stock or any Convertible Security.

 

(e) “Convertible
Securities” means any stock or other security (other than Options) that is at any time and under any circumstances,
directly or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles the holder thereof to acquire,
any shares of Common Stock.

 

(f)
“Fundamental Transaction” means that (i) the Company or any of its subsidiaries shall, directly or indirectly,
in one or more related transactions, (1) consolidate or merge with or into (whether or not the Company or any of its subsidiaries
is the surviving corporation) any other Person, or (2) sell, lease, license, assign, transfer, convey or otherwise dispose of
all or substantially all of its respective properties or assets to any other Person, or (3) allow any other Person to make a purchase,
tender or exchange offer that is accepted by the holders of more than 50% of the outstanding shares of Voting Stock of the Company
(not including any shares of Voting Stock of the Company held by the Person or Persons making or party to, or associated or affiliated
with the Persons making or party to, such purchase, tender or exchange offer), or (4) consummate a stock or share purchase agreement
or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement)
with any other Person whereby such other Person acquires more than 50% of the outstanding shares of Voting Stock of the Company
(not including any shares of Voting Stock of the Company held by the other Person or other Persons making or party to, or associated
or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination),
or (5) reorganize, recapitalize or reclassify the Common Stock, or (ii) any “person” or “group” (as these
terms are used for purposes of Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”) and the rules and regulations promulgated thereunder) is or shall become the “beneficial owner”
(as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of 50% of the aggregate ordinary voting power represented
by issued and outstanding Voting Stock of the Company.

 

(g) “Per
Share Market Value” means on any particular date (a) the closing sales price per share of the Common Stock on such
date on any registered national securities exchange on which the Common Stock is then listed, or if there is no such closing sales
price on such date, then the closing sales price on such exchange on the date nearest preceding such date, or (b) if the Common
Stock is not then listed on a registered national securities exchange, the closing sales price for a share of Common Stock in
the over-the-counter market, as reported by the OTC Bulletin Board or the OTC Markets Group, Inc. (or similar organization or
agency succeeding to its functions of reporting prices) at the close of business on such date, or (c) if the Common Stock is not
then reported by the OTC Bulletin Board or the OTC Markets Group, Inc. (or similar organization or agency succeeding to its functions
of reporting prices), the fair market value of a share of Common Stock as determined by the Company’s board of directors,
acting in good faith. In determining the fair market value of any shares of Common Stock no consideration shall be given to any
restrictions on transfer of the Common Stock imposed by agreement or by federal or state securities laws, or to the existence
or absence of, or any limitations on, voting rights.

 

(h) “Options”
means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities.

 

(i) “Person”
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
any other entity or a government or any department or agency thereof.

 

(j) “Voting
Stock” of a Person means capital stock of such Person of the class or classes pursuant to which the holders thereof
have the general voting power to elect, or the general power to appoint, at least a majority of the board of directors, managers
or trustees of such Person (irrespective of whether or not at the time capital stock of any other class or classes shall have
or might have voting power by reason of the happening of any contingency).

 

[signature
page follows]

 

    	 	8	 

    	 	 	 

    

 

IN
WITNESS WHEREOF, the Company and the Holder have caused this Warrant to Purchase Capital Stock to be duly executed as of the
Issuance Date set out above.

 

	 	NanoVibronix,
    Inc.
	 	 
	 	By:	                                
	 	Name:	 
	 	Title:	 

 

	 	Address:
    
	 	NANOVIBRONIX,
INC.
	 	525
EXECUTIVE BOULEVARD
	 	ELMSFORD
NY 10523
	 	GLOBIS
CAPITAL PARTNERS, L.P.

 

	 	By:	 
	 	Name:
    	 
	 	Title:	 

 

	 	Address:
    	 

 

    	 

    	 	 	 

    

 

EXHIBIT
A

 

EXERCISE
NOTICE

 

TO
BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS

WARRANT
TO PURCHASE CAPITAL STOCK

 

NanoVibronix,
Inc.

 

The
undersigned holder hereby exercises the right to purchase _________________ of the shares of Common Stock (“Warrant
Shares”) of NanoVibronix, Inc., a Delaware corporation (the “Company”), evidenced by Warrant
No. 2020-A (the “Warrant”). Capitalized terms used herein and not otherwise defined shall have the respective
meanings set forth in the Warrant.

 

1. Payment
of Exercise Price. The Holder shall pay the Aggregate Exercise Price in the sum of $___________________ to the Company in
accordance with the terms of the Warrant.

 

2. Delivery
of Warrant Shares. The Company shall deliver to Holder, or its designee or agent as specified below, ___________ shares of
Common Stock in accordance with the terms of the Warrant. Delivery shall be made to Holder, or for its benefit, to the following
address:

 

_______________________

_______________________

_______________________

_______________________

 

Date:
_______________ __, ______

 

	 	 
	Name
    of Registered Holder	 

 

	By:	    	 
	Name:	 	 
	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]